News | Proton Therapy | August 08, 2019

MD Anderson to Expand Proton Therapy Center

$159 million investment will double facility’s size, allowing more patients access to care

MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

August 8, 2019 ― The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a groundbreaking ceremony. The expansion will more than double the center’s size to more than 160,000 square feet – almost the size of three football fields – allowing more patients greater access to the most advanced and precise form of radiation therapy.

The estimated completion of the new building is November 2023. The $159 million expansion will be led by Gilbane Building Co. and will increase the center size to include a total of eight radiation therapy machines that rotate 360 degrees around a patient to deliver a proton beam to the exact area intended for treatment. The new machines, developed by Hitachi, will deliver intensity-modulated proton therapy (IMPT), the most precise form of image-guided radiation therapy (IGRT) available. The expansion also will include an additional synchrotron, the massive accelerator that creates the proton beam, as well as rooms with improved design for a better patient experience.

“For over a decade, MD Anderson has led the world in the field of proton therapy,” said Peter WT Pisters, M.D., president. “Our physicians and international cancer experts continue to push the boundaries to provide the most innovative care to our patients, and now we are working to provide increased access to that care so even more people can potentially benefit from this important treatment option.”

Proton therapy is an advanced type of radiation treatment that uses a beam of protons to deliver radiation directly to the tumor, destroying cancer cells while sparing healthy tissue. Protons enter the body with a low radiation dose, stop at the tumor, match its shape and volume or depth, and deposit the bulk of their cancer-fighting energy precisely at the tumor.

This therapy currently is used to treat a number of cancers in adult and pediatric patients, including prostate, lung, head and neck, liver, esophagus, brain and lymphoma, a cancer of the lymphatic system.

“This expansion is critical for patients who need access to proton therapy,” said Steven J. Frank, M.D., medical director of the Proton Therapy Center. “Our center has been operating at capacity, treating patients 20 hours a day, five days a week. Doubling our size will mean not only that we can treat more patients, but that we can do so using the very latest technology while achieving remarkable efficiency.”

Since opening in 2006, MD Anderson’s Proton Therapy Center has treated more than 9,300 patients from the United States and across the world within its current 73,500-square-foot facility. In 2018, MD Anderson treated 819 patients with proton therapy, a nearly 11 percent increase from 2017. Currently, 38 percent of patients are treated for head and neck cancers, but the center also sees numerous patients for prostate, lung, liver and brain cancers, as well as a range of pediatric cancers.

“As more patients become eligible for proton therapy, we want to make sure that those who need access to protons have the opportunity to receive them,” said Pisters. “This expansion will aid us in our efforts to provide the most-effective treatment for each patient, based on their specific disease.”

For more information: www.mdanderson.org

Related Content

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society

News | Radiation Oncology | January 13, 2020
January 13, 2020 — The cancer death rate declined
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewha
Lung cancer patients who are inactive prior to chemoradiation are less likely to tolerate treatment and more likely to see their cancer return
News | Lung Cancer | January 08, 2020
January 8, 2020 — Numerous ...
Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Feature | Radiation Oncology | January 03, 2020 | Dave Fornell, Editor
January 3, 2020 — Here is the top 20 pieces of radiation oncology content on the Imaging Technology News (ITN) websit
Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by an AI algorithm from RaySearch and is the subject of the No. 2 video on the list. Deep learning in radiology and radiation oncology.

Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by a machine learning algorithm from RaySearch and is the subject of the No. 2 video on the list. 

Feature | December 30, 2019
Here are the top 20 best performing videos posted on the Imaging Technology News website (ITN) from the past year, ba
Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter

Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter. Standard MRI or CT are not able to detect lymph node metastases smaller than 7 – 8 mm. Since most of the oncologic patients are dying due to metastases, a precise diagnostic is of utmost importance. The detection of small metastases, combined with the very clear and contrast rich MRI image of Ferrotran, enables an earlier and more precise treatment. Therefore, Ferrotran gives the patient a much higher chance of recovery.

News | Prostate Cancer | December 24, 2019
December 24, 2019 — SPL Medical announced today that the first patient has been successfully diagnosed with suspected
Beamscan MR for ViewRay MRIdian and for Elekta Unity

Beamscan MR for ViewRay MRIdian and for Elekta Unity

News | Radiation Therapy | December 23, 2019
December 23, 2019 — The Beamscan MR motorized 3-D...